Yonghong Zhu

Yonghong Zhu has a diverse and extensive work experience in the field of biopharmaceuticals. Yonghong is currently serving as the Chief Medical Officer at EpimAb Biotherapeutics, Inc. Prior to this, they held the same position at Maxinovel Pharmaceuticals Corp, Ltd, where they oversaw the clinical pipeline/strategy and organization, with a focus on solid tumor, liquid tumor, and autoimmune skin diseases.

Yonghong Zhu also worked at Roche Pharma Research and Early Development as a Translational Project Leader, leading project teams across China, Switzerland, the UK, and the USA/Canada. Yonghong has made significant contributions in the field of immunology, infectious diseases, and ophthalmology.

Before working at Roche, Yonghong Zhu served as the Executive Medical Director at Henlius and as the Senior Medical Director at Takeda, where they were involved in life cycle support and clinical development of precision medicine strategies in various therapeutic areas.

Yonghong also gained valuable experience at Genentech as a Senior Clinical Scientist in the Immunology & Infectious Diseases Global Development Group, focusing on personalized medicine strategies.

Yonghong Zhu's earlier experiences include working at Roche as a Biomarker & Experimental Medicine Leader in Clinical Research & Exploratory Development, at Sunesis Pharmaceuticals as a Translational Research Scientist, and at Osel, Inc. as a Scientist. Yonghong also worked as an industrial postdoctoral scientist at DNAX, Inc. (later renamed Schering-Plough Biopharma, Merck Research Lab Palo Alto).

Throughout their career, Yonghong Zhu has published select articles and papers, showcasing their contributions to the scientific community.

Yonghong Zhu holds a Ph.D. degree in Microbiology and Immunology from the University of Rochester School of Medicine and Dentistry. Prior to this, they completed a 7-year medical training program at Nanjing University School of Medicine, where they earned their MD in Medicine.